Abiraterone acetate in the treatment of prostate cancer

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Abhimanyu ThakurSugato Banerjee

Abstract

Among all cancer-related death, prostate cancer accounts for the second prominent reason for cancer-associated death in men. Despite the castration mediated reduction in testosterone synthesis, adrenal glands, as well as tissues of prostate cancer, continue to produce androgens, which ultimately lead to the growth of prostate cancer. This phase is referred as metastatic castration-resistant prostate cancer, which throws an obstacle to treatment. Androgen antagonists, in addition to deprivation of hormone, is being used for reducing the level of prostate-specific antigen but has not successfully come in front as a choice for prolonging the life of patients suffering from prostate cancer. In this prevailing scenario, abiraterone acetate (AA) has proved to be a boon for patients suffering from prostate cancer. AA selectively inhibits the actions of enzymes C17, 20-lyase and 17α-hydroxylase on cytochrome P450 (CYP) 17 when administered orally. The signaling of androgen receptor, being important for primary to metastatic phases of prostate cancer, CYP17 is essential for the synthesis of androgen. Herein, the in-detail pharmacological profile of AA, including androgen signaling, mechanism of action of AA, mechanism of AA resistance, ...Continue Reading

References

May 25, 1995·The New England Journal of Medicine·M E TaplinS P Balk
Mar 10, 1995·Archives of Biochemistry and Biophysics·M KatagiriM R Waterman
Sep 1, 1994·The Journal of Steroid Biochemistry and Molecular Biology·S E BarrieM Jarman
Feb 27, 2004·Biology of Reproduction·Sejal DhariaC Richard Parker
Oct 29, 2005·Science·Scott A TomlinsArul M Chinnaiyan
Nov 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I Scher, Charles L Sawyers
Dec 14, 2006·International Journal of Cancer. Journal International Du Cancer·Renée ChmelarNorman M Greenberg
Mar 27, 2007·Nature Reviews. Cancer·Angelo M De MarzoWilliam G Nelson
Apr 25, 2007·Proceedings of the National Academy of Sciences of the United States of America·Lao H SaalRamon Parsons
Jul 16, 2008·Current Opinion in Pharmacology·Timothy A YapJohann S de Bono
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles J RyanEric J Small
Oct 1, 2010·Current Oncology·S J Hotte, F Saad
Nov 26, 2010·The Journal of Steroid Biochemistry and Molecular Biology·Tadas S VasaitisVincent C O Njar
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Aug 3, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elahe A MostaghelR Bruce Montgomery
Aug 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles J Ryan, Donald J Tindall
Dec 12, 2012·The New England Journal of Medicine·Charles J RyanUNKNOWN COU-AA-302 Investigators
Jan 1, 2013·Anti-cancer Agents in Medicinal Chemistry·Francesco MassariGiampaolo Tortora
Jan 5, 2014·Cancer Metastasis Reviews·Zoran Culig, Frédéric R Santer
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Feb 28, 2015·American Journal of Clinical Oncology·Tu D DanRobert B Den
May 6, 2015·Expert Opinion on Drug Metabolism & Toxicology·Christopher Sejong HanIsaac Yi Kim
Jul 17, 2015·JAMA Oncology·UNKNOWN Global Burden of Disease Cancer CollaborationMohsen Naghavi
Sep 10, 2015·Microbiology Spectrum·Duane R HicklingXue-Ru Wu
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jul 1, 2016·Prostate International·Sangjun YooChoung-Soo Kim
Aug 5, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fangfang QuPhilip W Kantoff
Oct 19, 2016·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Luis Ramudo-CelaIsabel Martín-Herranz
Jan 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C MassardJ de Bono

❮ Previous
Next ❯

Citations

Mar 16, 2019·Clinical Chemistry and Laboratory Medicine : CCLM·Ruggero DittadiPaolo Carraro
Jul 8, 2020·Cancers·Giuseppe SaltalamacchiaErica Quaquarini
May 16, 2020·Current Pharmaceutical Design·Abhimanyu ThakurBabita Majhi
Apr 6, 2019·Anti-inflammatory & Anti-allergy Agents in Medicinal Chemistry·Vaishali C VenugopalAnjali Ranjan
Feb 19, 2019·Asian Journal of Urology·Tyler EtheridgeDavid F Jarrard
Apr 7, 2021·Journal of Bioenergetics and Biomembranes·Tingyan RuanJuying Zhou
Apr 24, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CarioliM Malvezzi
May 19, 2021·Nature Reviews. Urology·Soum D LokeshwarFred Saad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biosynthetic Transformations

Biosyntheic transformtions are multi-step, enzyme-catalyzed processes where substrates are converted into more complex products in living organisms. Simple compounds are modified, converted into other compounds, or joined together to form macromolecules. Discover the latest research on biosynthetic transformations here.

Related Papers

Clinical Advances in Hematology & Oncology : H&O
Charles J Ryan
The Journal of Urology
James L Mohler, Allan J Pantuck
Nature Reviews. Drug Discovery
Christopher J LogothetisPeter Kirkpatrick
The New England Journal of Medicine
Karim Fizazi, Kim N Chi
© 2022 Meta ULC. All rights reserved